MOSCOW, January 18. /TASS/. Turkmenistan has become the first country in Central Asia to officially register Russia’s Sputnik V vaccine, press service of the Russian Direct Investment Fund (RDIF) reported on Monday. The Ministry of Health and Medical Industry of Turkmenistan approved the vaccine under the emergency use authorization procedure without additional clinical trials, RDIF said.
"Turkmenistan became the first country in Central Asia to officially approve the use of the Sputnik V vaccine. Our partners highly appreciated the safety and efficacy of the vaccine, which is one of the world's leading vaccines against coronavirus and has already been approved by regulators in various regions of the world. Vaccination of the population with the proven Sputnik V vaccine created on a well-researched human adenoviral vectors platform is one of the key elements in preventing the spread of coronavirus," Kirill Dmitriev, CEO of RDIF, said as quoted by the press service.
Russia was the first in the world to register coronavirus vaccine on August 11, 2020, called Sputnik V. The drug was developed by the Gamaleya Research Institute of Epidemiology and Microbiology. Sputnik V is a vector vaccine based on the human adenovirus. The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela and Paraguay. The process to approve the vaccine in the EU has been initiated, RDIF said.